Like the licensed trivalent influenza vaccines, Fluzone Quadrivalent is a sterile suspension prepared from influenza viruses propagated in embryonated chicken eggs. The virus is harvested from the allantoic fluid, inactivated with formaldehyde, concentrated, purified in a linear sucrose density gradient solution using a continuous flow centrifuge, and finally chemically disrupted using a non-ionic surfactant, Octylphenol Ethoxylate (Triton® X-100) to produce a “split virus”. This split virus is then further purified and suspended in sodium phosphate-buffered isotonic sodium chloride solution. The upstream manufacturing processing of Fluzone Quadrivalent is identical to that for Fluzone High-Dose, and differs only in the formulation of the final bulk to a lower concentration per mL in order to achieve a 15 μg HA per strain/dose at a volume of 0.5 mL. Data derived from 3 consecutive batches of final bulk product demonstrated validation of the Fluzone Quadrivalent formulation process.

From FiercePharma:

According to the U.K. research firm, Sanofi’s Fluzone QIV, and other quadrivalents, should eclipse sales of three-strain vaccines over the next few years. It forecasts sales of Sanofi’s product should bring in $384 million in 2022 and predicts compound annual growth of nearly 14%. It said Sanofi’s Fluzone franchise of influenza vaccine products “is expected to help position the multinational vaccine manufacturer as a formidable player in the U.S. market.”Of course, it already is a formidable player. According to EvaluatePharma data, it is the top vaccine seller globally, with 2012 vaccine revenues topping $5.5 billion. Sanofi’s Fluzone/Vaxigrip flu shot is already one of the two top-selling vaccines along with PENT Act-HIB, a DTPq, Hib and polio vaccine. EvaluatePharma says those two should remain among the top 3 best sellers for another 5 years.

Disclaimer

The contents of VaxChoiceVT.com and related web sites are intended to provide useful information to the general public. All materials, including texts, graphics, images, and audio, on VaxChoiceVT.com are for informational purposes only and are not a substitute for medical diagnosis, medical or legal advice, or treatment for specific medical conditions. All visitors to VaxChoiceVT.com should seek expert medical care and consult their own health professional for any specific health issues and their own licensed attorney for legal advice. VaxChoiceVT.com does not recommend against or endorse specific tests, procedures, advice, or other information found on VaxChoiceVT.com. VaxChoiceVT.com and the Vermont Coalition for Vaccination Choice specifically disclaim all responsibility for any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use or application of any of the material on this site.